Health Care [ 9/12 ] | Biotechnology [ 22/73 ]
NASDAQ | Common Stock
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics.
Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.40 Decreased by -29.03% | -0.20 Decreased by -95.22% |
| Aug 15, 24 | -0.36 Increased by +5.26% | -0.11 Decreased by -227.27% |
| May 23, 24 | -0.21 Increased by +44.74% | -0.28 Increased by +25.00% |
| Mar 21, 24 | -0.42 Decreased by -10.53% | -0.35 Decreased by -20.00% |
| Nov 9, 23 | -0.31 Increased by +3.13% | -0.40 Increased by +22.50% |
| Aug 10, 23 | -0.38 Decreased by -31.03% | -0.35 Decreased by -8.57% |
| May 24, 23 | -0.38 Increased by +7.32% | -0.35 Decreased by -8.57% |
| Mar 23, 23 | -0.38 Increased by +58.24% | -0.33 Decreased by -15.15% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 4.93 M Decreased by -44.49% | -52.13 M Decreased by -67.02% | Decreased by -1.06 K% Decreased by -200.90% |
| Jun 30, 24 | 4.42 M Increased by +47.01% | -36.24 M Decreased by -0.75% | Decreased by -820.07% Increased by +31.47% |
| Mar 31, 24 | 5.29 M Decreased by -8.18% | -21.01 M Increased by +44.19% | Decreased by -397.11% Increased by +39.23% |
| Dec 31, 23 | 5.29 M Decreased by -35.49% | -21.01 M Increased by +55.40% | Decreased by -397.11% Increased by +30.86% |
| Sep 30, 23 | 8.88 M Increased by +26.29% | -31.21 M Increased by +21.21% | Decreased by -351.43% Increased by +37.61% |
| Jun 30, 23 | 3.01 M Decreased by -67.19% | -35.97 M Decreased by -76.76% | Decreased by -1.20 K% Decreased by -438.77% |
| Mar 31, 23 | 5.76 M Decreased by -37.12% | -37.64 M Decreased by -84.98% | Decreased by -653.41% Decreased by -194.19% |
| Dec 31, 22 | 8.20 M Increased by +97.63% | -47.10 M Decreased by -134.57% | Decreased by -574.39% Decreased by -18.69% |